Atara Biotherapeutics, Inc.'s eagerly awaited update on ATA188, its investigational off-the-shelf T-cell candidate for multiple sclerosis, turned out to be less than gripping, leaving analysts underwhelmed and investors spooked.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?